Antimicrobials & Antibiotic Resistance

About Conference

The 13th International Conference on Antimicrobials & Antibiotic Resistance April 01–02, 2027 Madrid, Spain is a premier global scientific meeting that brings together leading researchers, clinicians, microbiologists, pharmacologists, public health experts, and industry professionals to address one of the most urgent challenges in modern medicine—antimicrobial resistance (AMR). The conference serves as an international platform to share cutting-edge research, innovative treatment strategies, and the latest advancements in antimicrobial drug development, diagnostics, and infection control, fostering collaboration between academia, healthcare institutions, and pharmaceutical industries.

The scientific program of the conference will feature keynote lectures, plenary sessions, oral presentations, poster discussions, and interactive workshops covering a wide range of topics such as antibiotic discovery, resistance mechanisms, antimicrobial stewardship, novel therapeutics, and One Health approaches. Special emphasis will be placed on emerging technologies including AI-driven drug discovery, molecular diagnostics, phage therapy, and next-generation antimicrobial agents that are reshaping the future of infectious disease management.

Sessions & Tracks

Global Trends in Antimicrobial Resistance (AMR)

Global Trends in Antimicrobial Resistance (AMR) highlight one of the most critical challenges facing modern healthcare systems worldwide. AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to antimicrobial treatments, making infections harder to treat and increasing the risk of disease spread, severe illness, and death. It is estimated that bacterial AMR was associated with over 4.7 million deaths globally in 2021, emphasizing its growing impact on global health.

A key global trend is the steady rise in antibiotic resistance across multiple pathogens. According to recent surveillance data, approximately 1 in 6 bacterial infections worldwide were resistant to antibiotics in 2023, with resistance increasing in more than 40% of monitored pathogen–drug combinations between 2018 and 2023. This alarming growth is largely driven by the misuse and overuse of antibiotics in human medicine, agriculture, and animal health.

Mechanisms of Antimicrobial Resistance in Pathogens

Mechanisms of Antimicrobial Resistance in Pathogens focus on how microorganisms such as bacteria, viruses, fungi, and parasites evolve to survive exposure to antimicrobial agents. These resistance mechanisms reduce the effectiveness of drugs, making infections difficult to treat and increasing the risk of disease spread and complications.

One of the primary mechanisms is enzymatic degradation or modification of antibiotics, where pathogens produce enzymes (such as beta-lactamases) that inactivate antimicrobial drugs before they can act. Another important mechanism is alteration of drug targets, where genetic mutations modify the structure of microbial proteins or cellular components, preventing the drug from binding effectively.

Antimicrobial Drug Discovery and Development

Mechanisms of Antimicrobial Resistance in Pathogens focus on how microorganisms such as bacteria, viruses, fungi, and parasites evolve to survive exposure to antimicrobial agents. These resistance mechanisms reduce the effectiveness of drugs, making infections difficult to treat and increasing the risk of disease spread and complications.

One of the primary mechanisms is enzymatic degradation or modification of antibiotics, where pathogens produce enzymes (such as beta-lactamases) that inactivate antimicrobial drugs before they can act. Another important mechanism is alteration of drug targets, where genetic mutations modify the structure of microbial proteins or cellular components, preventing the drug from binding effectively.

Antimicrobial Stewardship and Rational Antibiotic Use

Antimicrobial Stewardship and Rational Antibiotic Use focuses on optimizing the use of antimicrobial agents to improve patient outcomes, reduce microbial resistance, and minimize unnecessary healthcare costs. Stewardship programs are essential in ensuring that antibiotics are prescribed only when needed, in the correct dose, duration, and route of administration.

The session will explore core components of antimicrobial stewardship programs (ASP), including evidence-based prescribing guidelines, diagnostic stewardship, formulary restrictions, and real-time monitoring of antibiotic use. These strategies help reduce inappropriate prescriptions and improve the effectiveness of treatments across healthcare settings.

Novel Antibiotics and Next-Generation Therapeutics

Novel Antibiotics and Next-Generation Therapeutics focuses on the development of innovative treatment strategies to combat drug-resistant infections and address the growing threat of antimicrobial resistance (AMR). With traditional antibiotics losing effectiveness, research is shifting toward advanced and targeted therapies that offer new mechanisms of action against resistant pathogens.

The session will explore new classes of antibiotics, antimicrobial peptides, and synthetic compounds designed to overcome resistance mechanisms. It will also highlight emerging approaches such as phage therapy, CRISPR-based antimicrobials, and microbiome-modulating therapies, which provide highly targeted and precision-based treatment options.

Molecular Diagnostics in Infectious Diseases 

Molecular Diagnostics in Infectious Diseases focuses on the use of advanced molecular techniques to detect, identify, and monitor pathogens with high accuracy and speed. These technologies have revolutionized infectious disease diagnostics by enabling early detection, precise identification of microorganisms, and improved patient management.

The session will explore key techniques such as polymerase chain reaction (PCR), real-time PCR, next-generation sequencing (NGS), and nucleic acid amplification tests (NAATs). These methods allow rapid detection of bacterial, viral, fungal, and parasitic infections, even at low concentrations, significantly reducing diagnostic turnaround time compared to conventional methods.

Clinical Microbiology and Infectious Disease Management

Clinical Microbiology and Infectious Disease Management focuses on the laboratory diagnosis, monitoring, and treatment of infectious diseases caused by bacteria, viruses, fungi, and parasites. This field plays a critical role in identifying pathogens, guiding antimicrobial therapy, and supporting infection prevention strategies in healthcare settings.

The session will explore microbiological techniques such as culture methods, microscopy, biochemical testing, and antimicrobial susceptibility testing (AST), which are essential for accurate pathogen identification and selection of appropriate treatment. Rapid diagnostic tools and automated systems are increasingly enhancing the speed and reliability of laboratory results.

One Health Approach to Antimicrobial Resistance

One Health Approach to Antimicrobial Resistance emphasizes the interconnected relationship between human health, animal health, and the environment in addressing the global challenge of antimicrobial resistance (AMR). Since resistant microorganisms can spread across humans, animals, food systems, and ecosystems, a unified and multidisciplinary approach is essential for effective prevention and control.

The session will explore how the use and misuse of antimicrobials in human medicine, veterinary practice, agriculture, and aquaculture contribute to the emergence and spread of resistant pathogens. It will highlight the transmission pathways of resistance through food chains, water sources, and environmental contamination, demonstrating the need for integrated surveillance systems.

Hospital-Acquired and Healthcare-Associated Infections (HAIs)

Hospital-Acquired and Healthcare-Associated Infections (HAIs) are infections that patients acquire during the course of receiving treatment for other conditions within a healthcare setting. These infections, including bloodstream infections, surgical site infections, ventilator-associated pneumonia, and urinary tract infections, pose significant challenges to patient safety, increase healthcare costs, and contribute to morbidity and mortality worldwide.

The session will explore the major causes and risk factors of HAIs, such as invasive medical procedures, prolonged hospital stays, compromised immune systems, and inadequate infection control practices. Particular emphasis will be placed on the role of multidrug-resistant organisms (MDROs), which make infections more difficult to treat and increase the burden on healthcare systems.

Vaccines as a Strategy to Combat AMR

Vaccines as a Strategy to Combat Antimicrobial Resistance (AMR) highlight the critical role of immunization in preventing infections and reducing the need for antimicrobial use. By lowering the incidence of bacterial and viral diseases, vaccines indirectly decrease antibiotic consumption and limit the emergence and spread of resistant pathogens.

The session will explore how existing vaccines (such as those for pneumococcal infections, influenza, and HPV) have already contributed to reducing infection rates and antibiotic prescriptions globally. Preventing infections at the source minimizes the need for treatment and helps preserve the effectiveness of current antimicrobial drugs.

Phage Therapy and Alternative Antimicrobial Strategies

Phage Therapy and Alternative Antimicrobial Strategies focus on innovative approaches to treat infections in the era of rising antimicrobial resistance (AMR). With conventional antibiotics becoming less effective, alternative therapies are gaining significant attention for their ability to target resistant pathogens with greater precision and reduced side effects.

The session will explore phage therapy, which uses bacteriophages—viruses that specifically infect and kill bacteria—as a targeted treatment for bacterial infections. Unlike broad-spectrum antibiotics, phages can selectively eliminate harmful bacteria while preserving beneficial microbiota, making them a promising solution for multidrug-resistant infections.

Infection Prevention and Control (IPC) Strategies

Infection Prevention and Control (IPC) Strategies are essential measures implemented in healthcare and community settings to prevent the spread of infections and ensure patient and staff safety. Effective IPC practices reduce the incidence of healthcare-associated infections (HAIs) and play a crucial role in controlling antimicrobial resistance (AMR).

The session will explore key IPC components, including hand hygiene, sterilization and disinfection of medical equipment, use of personal protective equipment (PPE), environmental cleaning, and safe waste management. These measures are fundamental in breaking the chain of infection and minimizing cross-contamination in clinical environments.

Genomics, Bioinformatics and AMR Surveillance

Genomics, Bioinformatics and AMR Surveillance focus on leveraging advanced genomic technologies and computational tools to monitor, understand, and combat antimicrobial resistance (AMR). These approaches enable high-resolution tracking of pathogens, identification of resistance genes, and improved outbreak detection across healthcare and community settings.

The session will explore the role of next-generation sequencing (NGS), whole-genome sequencing (WGS), and metagenomics in identifying microbial strains and resistance mechanisms at the genetic level. These technologies provide detailed insights into pathogen evolution, transmission pathways, and emerging resistance patterns that are not detectable through conventional methods.

Artificial Intelligence and Machine Learning in AMR Research

Artificial Intelligence (AI) and Machine Learning (ML) in AMR Research are transforming the way scientists understand, detect, and combat antimicrobial resistance. By analyzing large and complex datasets, AI-driven tools can identify resistance patterns, predict outbreaks, and support faster, more accurate clinical decision-making.

The session will explore how machine learning algorithms and deep learning models are used to detect antimicrobial resistance genes, classify pathogens, and analyze genomic and clinical data. AI-powered systems can process sequencing data and laboratory results to provide rapid insights into resistance mechanisms and guide targeted therapy.

Environmental and Agricultural Impact on AMR Spread

Environmental and Agricultural Impact on AMR Spread examines how the use of antimicrobials in agriculture, livestock, and environmental systems contributes to the emergence and dissemination of antimicrobial resistance (AMR). Antibiotics are widely used in animal farming for treatment, prevention, and growth promotion, which can lead to the development of resistant bacteria that spread through food chains, water, and soil.

The session will explore the role of agricultural practices, aquaculture, and environmental contamination in accelerating AMR. Residues of antibiotics and resistant microorganisms can enter ecosystems through farm runoff, wastewater discharge, and improper waste management, creating reservoirs of resistance genes in the environment.

Market Analysis

The global antimicrobial resistance (AMR) and antibiotics market is witnessing strong growth due to the rising burden of drug-resistant infections, increasing hospital-acquired infections, and expanding demand for advanced infectious disease diagnostics. The global antibiotic resistance market is valued at approximately USD 9–10 billion in 2025–2026 and is projected to reach around USD 14–18 billion by 2033–2035, growing at a CAGR of nearly 4.5%–6.7%, reflecting continuous investment in new antimicrobial therapies and diagnostic innovations.

A major driver of market expansion is the increasing prevalence of multidrug-resistant (MDR) pathogens such as E. coli, Klebsiella pneumoniae, Staphylococcus aureus, and Acinetobacter baumannii, which are creating urgent demand for novel antibiotics and alternative treatment strategies. The global healthcare system is facing significant economic pressure, with AMR linked to millions of infections and over a million deaths annually, highlighting the need for stronger antimicrobial stewardship programs and research investment.

Past Conference Report

Antibiotics Resistance 2026

The 12th International Conference on Antimicrobials & Antibiotic Resistance (Antibiotics Resistance 2026), held on April 02–03, 2026, in London, UK, was a highly successful international scientific conference that brought together leading microbiologists, infectious disease specialists, clinicians, researchers, pharmacologists, and public health professionals from across the world. The conference focused on addressing the growing global challenge of antimicrobial resistance (AMR) through knowledge sharing, scientific collaboration, and innovative research discussions aimed at improving infection control and antimicrobial stewardship worldwide.

The scientific program featured keynote lectures, plenary sessions, oral presentations, poster sessions, and interactive discussions covering key areas such as antibiotic resistance mechanisms, antimicrobial drug discovery, infectious disease management, clinical microbiology, and One Health approaches. Special emphasis was given to emerging solutions including novel antibiotics, alternative therapies, phage therapy, molecular diagnostics, and AI-based drug discovery, reflecting the latest advancements in combating drug-resistant infections.